of any international economic sanctions administered or enforced by the U.S. Department of State, the U.S. Department of the Treasurys Office of Foreign Assets Control, the United Nations
Security Council, the European Union, or the United Kingdom (including His Majestys Treasury) (collectively, the Authorities), nor is the Company or the Co-Issuer operating, organized or
resident in a country or territory to the extent such country or territory itself is the subject of sanctions administered or enforced by the Authorities (on the date hereof, the Crimea region and the
non-government controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine, the so-called Donetsk Peoples Republic, the
so-called Luhansk Peoples Republic, Cuba, Iran, North Korea and Syria); and the Issuers will not directly or, to their knowledge, indirectly use the proceeds of the offering of the Securities
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, to fund any activities of or business with any person, government, country, or territory that, at the time
of such funding, is the subject of sanctions administered or enforced by the Authorities. None of the representations and warranties given in this clause (y) shall be made to any Underwriter to the extent that they would mean a breach of
or result in a violation of or conflict with (1) Council Regulation (EC) No. 2271/1996, as amended from time to time (the EU Blocking Regulation), or any law or regulation implementing the EU Blocking Regulation in any member
state of the European Union or (2) the EU Blocking Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended, the EUWA) or any similar applicable U.S., U.K.
or EU anti-boycott law or regulation, as amended from time to time.
(z) To the knowledge of the Issuers, none of the Company nor its
subsidiaries is subject to Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse or such regulation as it forms part of domestic law in the United Kingdom by virtue of the EUWA or any related
implementing regulations (together, MAR).
(aa) None of the execution, delivery and performance by the Issuers of the
Transaction Documents, or consummation of the transactions contemplated thereby or by the Disclosure Package and the Final Prospectus, or the conduct or consummation of the offering, issuance and sale of the Securities, will conflict with, result in
a breach or violation of, or constitute a default under (i) any applicable law or (ii) the charter or by-laws, or the other organizational documents, as applicable, of either Issuer or (iii) the
terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or bound, or any judgment, order or decree applicable to the
Company or any of its subsidiaries of any court, regulatory body, administrative agency, governmental body or arbitrator having jurisdiction over the Company or any of its subsidiaries, except in the case of clauses (i) and (iii), as would not
have a Material Adverse Effect.
(bb) No consent, approval, authorization or other order of, or registration or filing with, any court or
other governmental or regulatory authority or agency is required for the execution, delivery and performance by the Issuers of the Transaction Documents, or consummation of the transactions contemplated thereby or by the Disclosure Package and the
Final Prospectus, except such as have been obtained or made and are in full force and effect and except as may be required under the Act or applicable state or foreign securities or blue sky laws.
(cc) This Agreement has been duly authorized, executed and delivered by each Issuer.
(dd) (i) The Base Indenture has been duly qualified under the Trust Indenture Act and has been duly authorized, executed and delivered by
the Company and constitutes a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other
similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles; (ii) the Ninth Supplemental Indenture has been duly qualified under the Trust Indenture Act and has been duly authorized, executed
and delivered by each Issuer and constitutes a valid and binding agreement of each Issuer, enforceable against each Issuer in accordance with its terms, except as may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles; and (iii) the Twelfth Supplemental Indenture has been duly authorized by each Issuer and, as of the Closing Date,
will have been duly qualified under the Trust Indenture Act and will have been duly executed and delivered by each Issuer, and will constitute a valid and binding agreement of each Issuer, enforceable against each Issuer in accordance with its
terms, except as may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.
6